Providing the COVID-19 Vaccines

PFIZER VACCINE: On August 23, 2021, FDA announced the first approval of a COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty, for the prevention of COVID-19 in individuals 16 years of age and older.

Pfizer-BioNTech COVID-19 Vaccine is authorized for emergency use and is available under the EUA as a two-dose primary series for individuals 5 years of age and older, as a third primary series dose for individuals 5 years of age and older who have been determined to have certain kinds of immunocompromise, and as a single booster dose for individuals 12 years of age and older at least five months after completing a primary series of the vaccine.

The Pfizer-BioNTech COVID-19 Vaccine is also authorized for use as a heterologous (or “mix and match”) single booster dose for individuals 18 years of age and older following completion of primary vaccination with a different available COVID-19 vaccine. For example, Moderna and Janssen COVID-19 vaccine recipients 18 years of age and older may receive a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine.

MODERNA VACCINE: Moderna COVID-19 Vaccine is available under EUA as a two-dose primary series for individuals 18 years of age and older, as a third primary series dose for individuals 18 years of age and older who have been determined to have certain kinds of immunocompromise, and as a single booster dose for individuals 18 years of age and older at least five months after completing a primary series of the vaccine.

The Moderna COVID-19 Vaccine is also authorized for use as a heterologous (or “mix and match”) single booster dose for individuals 18 years of age and older following completion of primary vaccination with a different available COVID-19 vaccine. For example, Pfizer-BioNTech COVID-19 Vaccine and Janssen COVID-19 vaccine recipients 18 years of age and older may receive a single booster dose of the Moderna COVID-19 Vaccine.

JANSSEN VACCINE: Janssen COVID-19 Vaccine is available under EUA as a single primary vaccination dose for individuals 18 years of age and older and as a single booster dose for individuals 18 years of age and older at least two months after completing primary vaccination with the vaccine.

The Janssen COVID-19 Vaccine is also authorized for use as a heterologous (or “mix and match”) single booster dose for individuals 18 years of age and older following completion of primary vaccination with a different available COVID-19 vaccine. For example, Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 vaccine recipients 18 years of age and older may receive a single booster dose of the Janssen COVID-19 Vaccine. View COVID-19 vaccine booster eligibility.

After providing the vaccine, recipients may have questions

Be sure to review the commonly reported local and systemic adverse events with recipients so they know what to expect:

  • RPain at the injection site (92%)
  • RFatigue (70%)
  • RHeadache (64.7%)
  • RMyalgia (61.5%)
  • RArthralgia (46.4%)
  • RChills (45.4%)
  • RNausea/vomiting (23%)
  • RAxillary swelling/tenderness (19.8%)
  • RFever (15.5%)
  • RSwelling at the injection site (14.7%)
  • RErythema at the injection site (10%)

Solicited local and systemic adverse reactions reported following administration of Moderna COVID-19 Vaccine had a median duration of 2 to 3 days. Share a copy of the Fact Sheet for Recipients and Caregivers and Moderna What to Expect Sheet to help prepare recipients